… CBP, p300, TIF2, NCOA2, ASXL2 or any other unknown genes that appear frequently in acute
myeloid leukemia [9]. … therapy against acute myeloid leukemia with MOZ fusion proteins. …

… Chromosomal translocations generate chimeric genes encoding fusion proteins of MOZ/MORF
and CBP/p300 HATs, inducing acute myeloid leukemia (Fig. 1) [[8, 54-57]]. MOZ also …

… homology of p300 to CBP, the MOZ gene was fused to the p300 gene in chromosome t (8;22) …
Image 6 Inhibited the activity of MOZ and MORF The effect on acute myeloid leukemia was …

… examine the genetic associations of t(8;16)(p11; p13) AML. In a third of the patients, … of CBP
fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia. …

… Leukemic fusion proteins such as MOZ-TIF2 and MLL-AFX constitutively activate CpG-rich
promoters by aberrantly recruiting p300/CBP. … Constitutive gene activation by MLL fusion …

… Examination by G-banding analysis, reverse transcription polymerase chain reaction (RT-PCR),
and Sanger sequencing of the therapy-related acute myeloid leukemia (AML). A) …

… Acute myelogenous leukemia (AML) is a hematological malignancy derived from hematopoietic
stem cells (HSCs) and myeloid progenitors with acquired fusion genes … /MORF inhibitor …

… Gene rearrangements of AF10 generate diverse AF10 fusion … leukemia, including acute
myeloid (AML), B-cell acute … of MOZ/MORF and DOT1L inhibition, we identified the genes directly …

… in primary sensitivity to CBP/p300 HAT inhibition we find that the acute transcriptional effects
of CBP/p300 HAT … mLL is fused to cBP, a histone acetyltransferase, in therapyYrelated …

… acute leukemias driven by MLL-X fusion oncogenes have led to the development of new
drugs, including inhibitors of bromodomain proteins [5,6,7], DOT1L [8, 9], and MENIN [10]… /CBP, …